Cargo Therapeutics provide corporate update for 2025

CARGO Therapeutics (CRGX) provided a corporate update and anticipated milestones for 2025. “2024 highlighted our excellence in execution and innovation. We now have three programs – two clinical-stage with another advancing quickly – all driven by our strong capabilities designing, developing, and delivering next-generation, and potentially curative cell therapies,” said Gina Chapman, President and Chief Executive Officer of CARGO. “We are on track to report our interim analysis results for FIRCE-1 in first half 2025. I am also delighted to announce the clearance of our IND for CRG-023, a potentially best-in-class CAR T-cell therapy with Phase 1 enrollment to initiate mid-year. Rapid progression of CRG-023 from lead construct to IND submission in less than 12 months was enabled by our robust CMC and pre-clinical development capabilities.”